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Abstract
Osteoarthritis is characterized by structural alteration of joints. Fibrosis of the synovial tissue is often detected and
considered one of the main causes of joint stiffness and pain. In our earlier proteomic study, increased levels of
vitronectin (VTN) fragment (amino acids 381–397) were observed in the serum of osteoarthritis patients. In this work,
the affinity of this fragment for integrins and its putative role in TGF-β1 activation were investigated. A competition
study determined the interaction of VTN(381–397 a.a.) with αVβ6 integrin. Subsequently, the presence of αVβ6 integrin was
substantiated on primary human fibroblast-like synoviocytes (FLSs) by western blot and flow cytometry. By
immunohistochemistry, β6 was detected in synovial membranes, and its expression showed a correlation with tissue
fibrosis. Moreover, β6 expression was increased under TGF-β1 stimulation; hence, a TGF-β bioassay was applied. We
observed that αVβ6 could mediate TGF-β1 bioavailability and that VTN(381–397 a.a.) could prevent TGF-β1 activation by
interacting with αVβ6 in human FLSs and increased α-SMA. Finally, we analyzed serum samples from healthy controls
and patients with osteoarthritis and other rheumatic diseases by nano-LC/Chip MS–MS, confirming the increased
expression of VTN(381–397 a.a.) in osteoarthritis as well as in lupus erythematosus and systemic sclerosis. These findings
corroborate our previous observations concerning the overexpression of VTN(381–397 a.a.) in osteoarthritis but also in
other rheumatic diseases. This fragment interacts with αVβ6 integrin, a receptor whose expression is increased in FLSs
from the osteoarthritic synovial membrane and that can mediate the activation of the TGF-β1 precursor in
human FLSs.
Introduction
Osteoarthritis (OA) is one of the most prevalent chronic
joint diseases. This condition is more common in women
and those over the age of 65, with a peak incidence around
the age of 75 years1,2. Its prevalence is increasing world-
wide due to the increasing rates of obesity and aging1. OA
is characterized by structural alterations in the whole joint
that typically exhibit cartilage degradation, subchondral
bone sclerosis, and osteophyte formation. However,
osteoarthritic synovium can also acquire an inflammatory
phenotype, as mostly encountered in rheumatoid arthritis
(RA), characterized by hyperplasia, leukocyte infiltration,
neoangiogenesis, and fibrosis3,4. Cartilage and synovial
fibrosis resulting from chronic inflammation and tissue
injury have only been recently highlighted in OA3,5,6.
Indeed, OA synovial tissue becomes rigid and thick, but
the mechanisms that underlie fibrosis are still elusive.
Synovial fibroblasts promote cell transformation into
myofibroblasts expressing α-smooth muscle actin 2 (α-
SMA) as well as excessive secretion of extracellular matrix
(ECM) components7. TGF-β is one of the main players in
fibrosis and is crucial for the fibrotic cascade activated in
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OA6. TGF-β is secreted in a latent form (pro-TGF-β),
which is biologically inactive and associated with a non-
covalent complex with the ECM. During biosynthesis,
pro-TGF-β dimerizes through disulfide, which links to
latent TGF-β-binding proteins (LTBPs) or glycoprotein-A
repetitions predominant protein in large latent com-
plexes. In response to injury, latent TGF-β complexes are
modified into active TGF-β according to a tissue- and
injury type-specific activation mechanism8. Integrin αVβ6
is known to activate the latent form of TGF-β1. Integrins
are receptors that connect the cytoskeleton to the ECM.
They are heterodimers made up of noncovalently asso-
ciated α and β subunits. In mammals, there are 18 dif-
ferent α subunits and 8 β subunits that can form 24
distinct heterodimers9,10. Integrins interact with different
ligands (e.g., fibronectin and vitronectin (VTN)) that are
mainly ECM molecules. They play an important role in
cell adhesion but also in cell movement and migration.
Integrins differ in tissue distribution and ligand identifi-
cation. Recently, it has been reported that αVβ5, αVβ3, and
αVβ6 interact with PRGD2, and their expression levels are
increased in osteoarthritic cartilage and osteophytes11.
Integrin αVβ6 interacts with molecules that contain the
Arg-Gly-Asp (RGD) motif. Its formation is determined by
β6 expression, since it can form a dimer only with αV,
while αV can interact with other β subunits (i.e., β1, β3, β5,
and β8)
12. Integrin αVβ6 is known to be involved in the
activation of TGF-β1 by interacting with the latency-
associated peptide (LAP) of TGF-β1 through its RGD
motif13. Integrin αVβ6 plays a role in fibrosis, as suggested
by Munger and colleagues, who observed that mice
lacking integrin αVβ6 were protected from pulmonary
fibrosis13. Indeed, in normal adult skin, kidney, lung, and
liver, epithelial cells have low or absent basal expression of
αVβ6 integrin, while it is upregulated in inflammation,
cancer, wounds, and fibrosis9,14. In a previous study, we
found increased levels of a V65 vitronectin fragment,
VTN(381–397 a.a.), in the synovial fluid and serum of OA
patients with respect to controls (healthy and RA sub-
jects)15. VTN is an ECM protein that participates in cell
migration, adhesion, and spreading16–18. This protein
interacts with αV-containing integrins and specifically
with αVβ3 integrin through its RGD motif
19. VTN also
plays a positive role in fibrosis18,20,21. Interestingly, the
fragment VTN(381–397 a.a.) is the result of VTN cleavage by
plasmin, which affects the interaction of plasminogen
activator inhibitor-1 (PAI-1) with VTN. Hence, PAI-1 is
no longer trapped in the ECM, can inhibit plasminogen
activation and may potentially mediate fibrosis22,23.
The aim of this work is therefore to investigate (i)
whether VTN(381–397 a.a.) can interact with integrin com-
plexes, (ii) if αVβ6 is expressed in synovitis in OA, (iii) if
αVβ6 can activate latent TGF-β1, and (iv) how
VTN(381–397 a.a.) can compete with TGF-β1. The presence




A competition study was performed to investigate the
interaction of VTN(381–397 a.a.) with five different integrins.
Radiolabeled echistatin, a disintegrin known to bind
integrin receptors, was used as a tracer for the binding
assays. Lyophilized echistatin was provided by Bachem
(Bubendorf, Switzerland) and radiolabeled by conjugation
with a radioiodinated benzoate (125ISIB) to the epsilon
amino group of lysine side chains. For the five integrins,
α5β1, αVβ1, αVβ3, αVβ5, and αVβ6 (R&D System; Minnea-
polis, MN, USA), a solution at 1.8 µg/mL was prepared
with integrin-binding buffer (IBB; 20 mM Tris pH 7.4,
150mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2).
Nunc Maxisorp Module plates were coated overnight at
4 °C with integrin complex at 1.8 µg/mL. After the wells
were washed with sample buffer (IBB, 0.5% BSA), block-
ing solution (IBB, 2% BSA) was added, and the microplate
was incubated for 2 h at room temperature. The wells
were then washed three times with IBB/0.5% BSA. Then,
125ISIB-echistatin was diluted in sample buffer to fixed
concentrations of 4, 4, 8, 8, and 20 nM for α5β1, αVβ1,
αVβ3, αVβ5, and αVβ6 competition studies, respectively.
The 125ISIB-echistatin was mixed with sample buffer at a
ratio of 1:1 (total binding= control well) or with
increasing concentrations of ligands (Supplementary
information SI1) [complete VTN, VTN(381–397 a.a.),
VTN(365–381 a.a.)] at a ratio 1:1 and added to wells in
duplicate. We used 1,4,7-triazacyclononane-1,4,7-triacetic
acid (NOTA) as a negative control. Then, 100 µL of pre-
pared solutions (125ISIB-echistatin and ligands) was added
to the plate and incubated for 2 h at room temperature
with agitation. After rinsing, bound radioactivity was
quantified using a gamma counter. The percentage of
relative binding of radiolabeled echistatin was calculated
as follows: radioactivity in the test well*100/radioactivity
in the reference well. The reference well represents the
total binding without ligand. For comparison of the
potency of ligands in inhibiting bound 125ISIB-echistatin
for different integrin complexes, the half-maximal inhi-
bitory concentration (IC50) was calculated. The IC50 value
was determined by constructing a dose–response curve
and examining the effect of different concentrations of
ligands on 125ISIB-echistatin binding. The experimental
data were subjected to nonlinear regression using a five-
parameter logistical model with GraphPrism 7 software.
Primary cell culture and treatment
Synovial membranes were obtained from 22 OA patients
(14 females, 8 males; mean age 69.8 ± 9.6 years, BMI 30.9 ±
6.8) during knee replacement, and primary synovial
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fibroblasts were isolated as explained previously24. The
research ethics committee of CHU de Liege (Belgium)
approved the study, and the patient gave informed consent to
allow research procedures on samples. Human fibroblast-like
synoviocytes (FLSs) were then cultured in DMEM supple-
mented with 10% FBS, 1% Pen/Strep, and 1% L-glutamine (all
from Lonza; Basel, Switzerland) at 37 °C in an atmosphere of
5% CO2. In a plate, 5 × 10
4 FLSs were stimulated with dif-
ferent compounds to analyze the modulation of αVβ6: (i)
TGF-β1, TNF-α, IL-1β, or IL-6 were used for 3 or 7 days at a
concentration of 10 ng/mL; (ii) among the danger-associated
molecular patterns, high-mobility group box 1 (HMGB1) was
tested at 10, 50, and 100 ng/mL for 3 days, while S100A9 and
S100A12 were tested at 100 and 200 ng/mL for 3 days or
24 h; (iii) advanced glycation end product (AGE-BSA) was
tested at 50, 100, and 200 μg/mL for 3 days or 24 h; (iv)
prednisolone and dexamethasone were used at 1 μM
for 3 or 7 days; and (v) menadione or H2O2 was used to
induce oxidative stress at 25–50–100 μM (3 h) and
100–200–400 μM (2 h), respectively, without FBS in the
medium.
Finally, for analysis of the expression of α-SMA, FLSs
(n= 5) were stimulated with VTN(381–397 a.a.) (10, 25, 50,
100 ng/mL) with or without TGF-β1 (10 ng/mL) for
7 days.
Western blot
The expression of αV and β6 subunits and α-SMA in
FLSs was evaluated by western blot analysis. Cells were
scraped from plates and lysed with lysis buffer (25 mM
HEPES, 150 mM NaCl, 0.5% Triton, 10% glycerol, 1 mM
dithiothreitol) containing phosphatase inhibitors (25 mM
β-glycerophosphate, 1 mM Na3VO4, and 1 mM NaF) and
complete protease inhibitor mixture (Roche Applied Sci-
ence; Penzberg, Germany). Total proteins were separated
by 10% SDS–PAGE gels (12% for α-SMA) and transferred
onto PVDF membranes. The membranes were then
incubated with anti-αV polyclonal antibody (1:250 dilu-
tion) (Cell Signaling Technology; Boston, MA, USA), anti-
β6 polyclonal antibody (1:1000 dilution) (Abcam; Cam-
bridge, UK) or anti-α-SMA monoclonal antibody (Agilent;
Santa Clara, CA, USA; 1:1000 dilution). HRP-conjugated
anti-rabbit antibody (1:1000 dilution) (Cell Signaling
Technology) was used as the secondary antibody.
Immunoblots were developed using the ECL chemilumi-
nescent detection system. Rabbit anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (Merck) or rabbit
anti-heat shock protein 90 (Hsp90; Santa Cruz) was used
as loading controls at a dilution of 1:10,000 or 1:200,
respectively. Values of optical intensity were normalized
to GAPDH or Hsp90 levels. Data were analyzed by paired
Wilcoxon test; a p-value < 0.05 was considered statistically
significant. Statistical analysis was performed with
GraphPad Prism 6 software (San Diego, CA, USA).
Flow cytometry
Flow cytometry fluorescence-activated cell sorting
(FACS) was applied to detect the presence of αVβ6
integrin in FLSs. FLSs (n= 4) were detached by scraping
and harvested on ice-cold PBS containing 1mM MgCl2
and 0.1% BSA; 4 × 105 cells were used for each condition.
The cell scraper was used to prevent ablation induced by
trypsin, and the experiment was performed on ice to
prevent integrin internalization25. U87 glioblastoma cells
that naturally expressed αVβ6 integrin were used as a
positive control26. Primary antibody recognizing αVβ6
integrin (Merck; Darmstadt, Germany) was used at a
concentration of 100 µg/mL in PBS/MgCl2/BSA. After
incubation for 40 min on ice and two washes with PBS/
MgCl2/BSA, the cells were incubated for 20min on ice in
the dark with Alexa Fluor 647-conjugated goat anti-
mouse antibody (Thermo Fisher Scientific). After two
washes, the cells were resuspended in 500 µL of PBS/
MgCl2/BSA and filtered with a 100 µm strainer (Sysmex;
Norderstedt, Germany) in FACS tubes; 1 µL of DAPI dye
(Thermo Fisher Scientific) was added to identify dead
cells. Flow cytometric measurements were performed
with a FACSCantoTM II (BD Biosciences; San Jose, CA,
USA), and 104 cells were analyzed in each assay. Flow
cytometry standard files were then analyzed by FlowJoTM
software (BD Biosciences).
Immunohistochemistry (IHC) of formalin-fixed paraffin-
embedded tissues
Synovial biopsies (n= 23) were collected from synovial
membranes provided from OA (n= 9), chronic pyr-
ophosphate arthropathy (CPPA) (n= 7), and RA patients
(n= 7) by needle arthroscopy from the affected knees
(Table 1). These biopsies were fixed in 4% paraf-
ormaldehyde for 24 h at 4 °C, embedded in paraffin and
characterized according to the histological inflammatory
score (HIS) based on Tak’s score27. Briefly, HIS was
obtained by hematoxylin-eosin staining measuring
hyperplasia (0–4), infiltration of lymphocytes (0–4),
plasma cells (0–4) and neutrophils (0–3) and by IHC for
the infiltration of macrophages (CD68 staining, 0–3),
leading to a total HIS of 18. The greater the score was, the
greater the inflammatory status was.
For IHC, slides were first incubated overnight at 65 °C.
The day after, sections were dewaxed in xylene and sub-
sequently passed through 100% ethanol and 70% ethanol.
The unmasking was performed at 80 °C for 20min.
Endogenous peroxidase activity was then inactivated with
3% H2O2 for 20min followed by blocking. Specific anti-
bodies for β6 (Abcam) or α-SMA (Agilent) were used O/N
diluted 1/500 or 1/50, respectively. Rinsed slides were
incubated with HRP-labeled anti-rabbit antibody (Agi-
lent) in a humidified chamber for 30min at RT. Perox-
idase was revealed with a Liquid DAB+ Substrate
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Chromogen System (Agilent) for 10 min in a humidified
chamber. Rinsed sections were counterstained for 30 s
with Carazzy’s hematoxylin. Staining was detected with a
Nanozoomer Digital Pathology 2.0 HT scanner (Hama-
matsu Photonics, Hamamatsu, Japan). Images derived
from IHC were analyzed with the bioimage analysis
software QuPath28.
TGF-β bioassay
Transformed mink lung epithelial cells (TMLCs), a
generous gift from Prof. DB Rifkin (Department of Cell
Biology, NYU School of Medicine, New York, NY), were
used to test TGF-β1 functionality29. TMLCs were cul-
tured in DMEM supplemented with 10% FBS, 1% Pen/
Strep, and 1mg/mL G418 Sulfate (Biowest; Riverside,
MO, USA). For coculture, TMLCs were plated in 96-well
plates at a density of 104 cells per well, and fibroblasts
were added at a density of 1.5 × 104 cells per well, with a
final volume of 100 μL. Cells were allowed to attach at
37 °C and 5% CO2. After 6 h, the medium was removed
and replaced by the different treatments diluted in med-
ium with 0.1% BSA without FBS (final volume of 100 μL).
For function-blocking experiments, cells were incubated
with anti-αVβ6 antibody (clone 10D5; Merck) or with the
isotype control IgG2a kappa (clone eBM2a; Thermo
Fisher Scientific) for 20min at room temperature at a
concentration of 50 μg/mL in medium containing 1mM
MgCl2/0.1% BSA before adding other compounds.
Human latent TGF-β1 (hlatent TGF-β1; Cell Signaling
Technology) was added at a concentration of 200 ng/
mL30. For acidic activation, hlatent TGF-β1 was incubated
for 10min with 1 N HCl and neutralized by 1.2 N NaOH/
0.5M HEPES before it was added to cells. VTN(381–397 a.a.)
(Thermo Fischer Scientific) and hepcidin were used at
50 ng/mL. After 16 h of incubation at 37 °C and 5% CO2,
the cells were washed with PBS and lysed by using 75 μL
of cell culture lysis reagent (Promega, Madison, WI, USA)
for 30 min at room temperature on a plate shaker. Luci-
ferase activity was assessed by plate-reading luminometers
with an injector (Victor™ X3; PerkinElmer Waltham, MA,
USA) adding 100 µl of luciferase assay reagent (Promega)
per well. Each condition was performed in triplicate for
six different donors.
The data are expressed as relative luciferase activity
(RLA). RLA is the measured luciferase activity of the
coculture divided by the activity of the related control
alone under the same conditions. Data were analyzed with
the paired Wilcoxon test for non-normal data; a p-value <
0.05 was considered statistically significant. Statistical
analysis was performed with GraphPad Prism 6 software.
Serum collection
Thirty-eight healthy subjects and 38 OA patients were
enrolled in the study to quantify the expression of the V65
fragment of VTN (381SQRGHSRGRNQNSRRPS397) or
VTN(381–397 a.a.). Blood samples were also collected from
patients with different chronic inflammatory diseases: 46
with RA, 30 with ankylosing spondylitis (AS), 23 with
systemic lupus erythematosus (SLE), and 20 with systemic
sclerosis (SSc). OA patients were sorted into the early OA
(n= 13) and late OA (n= 25) groups according to the
K&L score. Data of the participants are summarized in
Table 2. Human blood samples were collected under
standard conditions and allowed to coagulate in plain
glass tubes. Serum was obtained after centrifugation at
3000 rpm for 10 min at room temperature. Aliquots of
supernatants were prepared and stored at −80 °C until
use. The study was approved by the local institutional
review boards of CHU Hospital of Liège.
Nano-LC/Chip MS–MS
The levels of the V65 fragment of VTN in serum
samples were analyzed as previously described31. Briefly,
serum samples and calibration solution were purified and
concentrated on an Oasis μElution WCX 96-well plate
(Waters Corporation, Dublin, Ireland) before chromato-
graphic separation and mass spectrometry analysis.
ProtID-chip Zorbax 300SB (5 μm C18 phase, Agilent
Technologies; Santa Clara, CA, USA) was used for chro-
matographic separation in gradient mode. A nanochip ESI
source was operating in positive mode, and protonated
peptide detection was performed by ion trap mass spec-
trometry (Agilent Technologies, Ion Trap LC/MS
G6340A). The MS and MS/MS experimental parameters
were optimized to be as sensitive and selective as possible.
Table 1 Clinical features of patients from whom synovial
biopsies were collected after needle arthroscopy of
the knee.
OA CPPA RA
No. 9 7 7
Female (no.) 8 5 5
Age (median ± SD) 55 ± 14 65 ± 9 61 ± 17
BMI (median ± SD) 33 ± 7 24 ± 4 24 ± 5
ESR+ 1/9 0/7 3/7
CRP+ 2/9 3/7 6/7
RF+ 0/9 0/7 2/7
Anti-CCP+ 0/9 0/7 2/7
K&L score-median (interval) 3 (0–4) 2 (0–4) n.d.
Histological inflammatory score median
(interval)
4 (3–8) 5 (5–13) 14 (12–17)
OA Osteoarthritis, CPPA chronic pyrophosphate arthropathy, RA rheumatoid
arthritis patients, BMI body mass index, ESR erythrocyte sedimentation rate, CRP
C-reactive protein, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated
peptide, K&L score Kellgren and Lauwrence score peptide.
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The intensities of the selected product ions were summed
to extract ion chromatograms and subsequently inte-
grated (QuantAnalysis software, Bruker Daltonik GmbH;
Billerica, MA, USA). Area ratios (peptide vs. labeled
peptide) were considered for quantitation. The linearity of
the results for fragment quantitation was validated in the
concentration range of 2.5–100 ng/mL, and the limit of
detection was 0.76 ng/mL.
Differences in expression of VTN(381–397 a.a.) among
the examined classes of patients were analyzed
with the unpaired Kolmogorov–Smirnov tests for
nonparametric data.
Results
Integrin binding specificity of VTN(381–397 a.a.)
To determine if VTN(381–397 a.a.) could interact with
integrins, we investigated its ability to compete with
radiolabeled echistatin for binding to five different
integrin complexes: α5β1, αVβ1, αVβ3, αVβ5 and αVβ6. We
also tested the binding affinity of the whole VTN protein
and another VTN fragment, VTN(365–381 a.a), as previously
described by Maile et al. 32,33. First, the binding affinity of
echistatin to the five integrins was measured by deter-
mining the equilibrium dissociation constant (KD). KD
was evaluated by saturation assays involving addition of
increasing concentrations of radiolabeled echistatin to a
constant concentration of integrins (coated at 1.8 µg/mL).
The KD values calculated for each integrin complex were
1.48, 0.99, 3.17, 3.46, and 17.05 for α5β1, αVβ1, αVβ3, αVβ5,
and αVβ6, respectively. Subsequently, competitive experi-
ments were performed using increasing concentrations of
ligand and a fixed amount of radiolabeled echistatin.
The fixed concentration of radiolabeled echistatin was
determined according to its KD value. For each ligand
concentration, the relative binding of 125ISIB-echistatin to
coated integrins was then measured, and values were
plotted versus the logarithm of ligand concentration.
These competition curves together with the derived IC50
values are shown in Fig. 1. The VTN(381–397 a.a.) peptide
exhibited binding affinity only for integrin αVβ6 (IC50=
3.2 µM), as also observed with the other VTN(365–381 a.a.)
fragment (IC50= 0.79 µM). The whole VTN protein also
exhibited a high affinity for αVβ6 (IC50= 0.25 µM) but also
for αVβ3 (IC50= 1.5 µM) and αVβ5 (IC50= 0.13 µM), as
expected.
Therefore, considering that (i) the levels of cleaved
VTN(381–397 a.a.) fragments were increased in the serum
and synovial fluid of OA patients15 and (ii) this fragment
interacts with integrin αVβ6, we investigated the expres-
sion of αVβ6 integrin in OA synovial tissue.
Integrin αVβ6 expression in FLSs and OA-related synovitis
In vitro and in situ expression of αV and β6 subunits or the
αVβ6 complex on FLSs
First, the expression of each subunit of the αVβ6 integrin
was observed by western blot analysis using human FLSs
provided from the synovial membrane of OA patients
(Fig. 2a). Second, the expression of the αVβ6 integrin
complex was determined by FACS analysis and illustrated
by a flow cytometric histogram obtained with human
FLSs previously incubated with αVβ6 antibodies (Fig. 2b).
As a negative control, FACS analysis was applied to FLSs
incubated with only the secondary antibody (to exclude
any nonspecific binding with the secondary antibody) and
to FLSs with no antibody (to control the background
derived from autofluorescence). Cells positive for DAPI
were considered dying and were excluded from analysis
by gating. The mean fluorescence intensity (MFI ± SD)
Table 2 Clinical characteristics of patients enrolled in the study.
HC early OA late OA RA AS SLE SSc
n 38 13 25 46 30 23 20
% Female 63 77 84 70 40 87 55
Age-median (range) 48 (24–72) 64 (51–77) 68 (61–86) 55 (17–77) 50 (23–71) 42 (17–68) 57 (37–83)
BMI-Median (range) 23 (19–28) – – 25 (16–40) – 22 (17–31) 24 (19–32)
DAS (range) – – – 4.2 (0.5–8) – – –
ESR% – 9 11 57 40 24 15
CRP+% – 18 21 47 45 15 45
RF+% – 0 0 63 – – –
Anti-CCP+% – 0 0 85 – – –
HLA-B27+% – – – – 86 – –
HC healthy control, OA osteoarthritis, RA rheumatoid arthritis, AS ankylosing spondylitis, SLE systemic lupus erythematosus, SSc systemic sclerosis, BMI body mass
index, DAS disease activity score, ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide, HLA-B27
human leukocyte antigen.
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obtained with human FLSs (n= 4) was significantly shif-
ted from 53 ± 21 to 134 ± 29 in the presence of αVβ6
antibody (p-value= 0.002). No significant variation in
MFI was observed with the secondary antibody (Fig. 2b).
However, it is noteworthy that strong basal auto-
fluorescence of human FLSs was observed compared to
control U87 cells (33 ± 3.2, data not shown). Supple-
mentary information SI2 illustrates three other patients
whose FLSs were analyzed by FACS.
These data confirmed the presence of the αVβ6 integrin
antibody on the cellular surface of the cellular membrane
in FLSs from the OA patients. To confirm the presence of
the αVβ6 integrin in situ, we performed IHC analysis of
synovial membranes provided from healthy individuals
and OA patients and used an antibody directed against
the β6 subunit (Fig. 2c).
Increased expression of the β6 subunit in FLSs and arthritic
synovitis under profibrotic conditions
We then wanted to evaluate whether the expression of
the αV and β6 subunits could be modulated in human
FLSs by (i) a profibrotic mediator (TGF-β1), (ii) proin-
flammatory cytokines (TNF-α, IL-1β, and IL-6), (iii)
danger-associated molecular patterns (HMGB1, S100A9,
S100A12), (iv) advanced glycation end products (AGE-
BSA), (v) drugs (prednisolone, dexamethasone), and (vi)
oxidative stress (menadione, H2O2). We observed that
none of these treatments influenced the expression levels
of the αV and β6 integrin subunits (Supplementary
information SI3), except TGF-β1, which significantly
increased β6 expression (n= 12) (Fig. 2d and e).
Accordingly, β6 expression was evaluated in synovial tis-
sues provided from the patients with OA (n= 9), CPPA
Fig. 1 Results of the competition study. Competition curves between 125ISIB-echistatin and ligands on the recombinant human integrins αVβ6,
α5β1, αVβ1, αVβ3, and αVβ5. The ligands were vitronectin (VTN) fragment 381–397 aa, VTN fragment 365–381 aa, and total VTN. NOTA was used as
negative control. The IC50 values of ligands able to inhibit the echistatin interaction with recombinant human integrins are indicated.
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(n= 7), and RA (n= 7). These biopsies were characterized
by the α-SMA expression level, a fibrotic marker, as well
as by HIS based on the following features: hyperplasia and
infiltration of lymphocytes, plasma cells, neutrophils and
macrophages, resulting in an HIS ranging from 0 to 18.
The highest value of 18 represents the most inflamed
synovitis. First, the β6 subunit was detected by IHC in
23 synovial biopsies. β6 staining was judged positive by the
presence of brown staining in the cytoplasm (Fig. 3a).
Then, with Spearman correlation analysis, a statistically
significant correlation was observed between the β6 per-
centage and α-SMA expression (r= 0.64, p-value= 0.001)
and, to a lesser extent, between the β6 percentage and HIS
(r= 0.45, p-value= 0.031), confirming the in vitro results
(Fig. 3b).
Human FLSs activate human latent TGF-β
Integrin αVβ6 is known to play a role in fibrosis
13 and in
the activation of latent TGF-β1, a profibrotic mediator
once activated34. Based on our previous results, we wan-
ted to confirm that (i) latent TGF-β1 could be activated in
the presence of osteoarthritic FLSs and that (ii) the
VTN(381–397 a.a.) peptide could interact with αVβ6.
A quantitative TGF-β bioassay was applied to evaluate
the activation of the TGF-β1 precursor based on its ability
to induce PAI-1 expression. For this purpose, TMLCs
were stably transfected with a construct containing the
PAI-1 promoter fused to luciferase. In the presence of
bioactive TGF-β1, increased PAI-1 expression resulted in
a dose-dependent increase in luciferase activity in the cell
lysates29. Low pH and interaction with integrin αVβ6 are
two mechanisms known to activate latent TGF-β135.
Therefore, to determine whether human FLSs can
enhance TGF-β1 activation, we performed coculture with
FLSs and TMLCs in the presence of latent TGF-β1. First,
we observed that FLSs (n= 14) did not spontaneously
produce a notable amount of active TGF-β1 in coculture,
as shown in Fig. 4a. However, we observed a significant
Fig. 2 In vitro and in situ expression of the αV and β6 subunits or the αVβ6 complex on FLSs. a Expression of the αV and β6 subunits shown by
western blots of human fibroblast-like synoviocytes (FLSs) from four representative patients. b FACS histograms of flow cytometric analysis of FLSs
from a patient with OA. Profiles of cell surface expression of the αVβ6 integrin (dark gray) and controls: secondary antibody (Ab) alone (light gray) and
autofluorescence (AF; lighter gray). This is the result from a representative patient; in supplementary information SI2, histograms from three other
patients are shown. c Immunohistochemistry of human synovial membranes. Representative images of β6 in biopsies from a healthy donor (control)
and an OA patient. d Representative images and quantification e of β6 signaling after TGF-β1 treatment. Values were normalized to that of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). **p-value ≤ 0.01.
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activation of latent TGF-β1 when FLSs were present,
similar to TGF-β1 activation under acidic conditions
(Fig. 4b). This finding strongly suggests that TGF-β1
activation is mediated by FLSs. Further, to confirm that
αVβ6 integrin was involved in this activation, we per-
formed function-blocking experiments. Anti-αVβ6 anti-
body was added to the coculture (n= 6), and a significant
reduction in the activation of latent TGF-β1 was observed
in a concentration-dependent manner (Fig. 4c). No sig-
nificant variation was observed with the isotype control
(Fig. 4d). Interestingly, when VTN(381–397 a.a.) was added
to the coculture (n= 6), the luciferase signal decreased,
suggesting that this fragment can prevent the interaction
of latent TGF-β1 with αVβ6 integrin. No significant var-
iation was observed with hepcidin, which was used as a
control peptide (Fig. 4e). All the results are presented as
the mean (±SEM) of RLA.
Expression of α-SMA in FLSs
FLSs were stimulated with VTN(381–397 a.a.) with or
without TGF-β1 to evaluate the effect on the expression
of the fibrotic marker α-SMA (Fig. 5). As expected, TGF-
β1 upregulated the content of the fibrotic marker α-SMA
and the presence of VTN(381–397 a.a.) did not change this
effect. Interestingly, when FLSs were treated with
VTN(381–397 a.a.) at 10 ng/mL, we observed a significant
increase in α-SMA. Therefore, these preliminary results
suggested a profibrotic effect for the VTN fragment. The
results in Fig. 5 are expressed as the ratio of the nor-
malized optical density vs. the control and are shown as
the mean (±SEM).
Quantification of VTN(381–397 a.a.)
To confirm the increased expression of VTN(381–397 a.a.)
in OA, we performed nano-LC/Chip MS–MS of serum
samples from the healthy controls and the patients with
OA or with different chronic inflammatory diseases: RA,
AS, SLE, and SSc. We confirmed that the VTN(381–397 a.a.)
levels were increased in serum from the late OA patients
compared to the healthy controls (p-value= 0.004). Fur-
thermore, we observed a significant increase in this frag-
ment in the patients with SLE and SSc compared to the
Fig. 3 Expression of β6 in synovial membranes. a Immunohistochemistry on human synovial membranes. Representative images of β6 and α-SMA
expression in biopsies from two different OA patients (P). b Spearman correlation analysis was applied to examine the correlation of the β6
percentage with the total histological inflammatory score (HIS) and α-SMA; r= Spearman coefficient. OA Osteoarthritis, CPPA chronic pyrophosphate
arthropathy, RA rheumatoid arthritis.
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healthy subjects, with p-values of 0.003 and <0.001,
respectively (Fig. 6).
Discussion
The present work relies on our previous proteomic
studies, which highlighted the presence of a specific VTN
fragment, VTN(381–397 a.a.), in the serum and synovial
fluid of patients with OA15,31. VTN(381–397 a.a.) is a peptide
composed of 17 amino acids at the C-terminal end of the
V65 VTN subunit (a.a. 20–398) in the heparin-binding
domain (HBD). VTN is a multifunctional ubiquitous
glycoprotein produced by the liver that is secreted mostly
as a serum protein and as a component of the ECM36.
This molecule is also present in platelets and various
human tissues37. This protein is involved in cell pro-
liferation, differentiation, adhesion, and the immune
response since it participates in fibrinolysis, coagulation,
and the activation of the complement system37–39. Levels
of VTN increased in pathological conditions related to
acute inflammation such as RA and severe sepsis, where it
Fig. 4 TGF-β luciferase bioassay. TMLCs and human FLSs were cultured for 16 h and lysed to measure luciferase activity. a Spontaneous production
of active TGF-β: comparison between TMLCs and cocultures (TMLC+ FLSs). b Activation of human latent TGF-β by acidic activation or by the
presence of human FLSs. c and d Function blocking experiments with anti-αVβ6 antibody. There was a reduction in TGF-β activation dependent on
increasing concentrations of the anti-αVβ6 antibody (20–50–100 μg/mL) (c). No reduction was observed with the isotype control (IC). IC and anti-αVβ6
were used at 50 μg/mL (d). e Effect of the presence of the V65 vitronectin (VTN) fragment or peptide control (50 ng/mL). Human latent TGF-β was
used at 200 ng/mL. The results are expressed as the relative luciferase activity (RLA) and are shown as the mean (±SEM). *p-value < 0.05; ***p-value ≤
0.0001.
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seems to contribute to organ injury39–41. Moreover, its
rising levels are considered a marker of fibrotic tissues
(e.g., in liver and lung)42–44. Notably, VTN(381–397 a.a.) is a
cleaved fragment of VTN obtained by plasmin activation,
reducing the affinity between VTN and PAI-1 and, con-
sequently, fibrinolysis22.
In this study, we started to move towards a functional
investigation of the role of VTN(381–397 a.a.) in OA. VTN is
known to interact with integrin receptors by its RGD motif,
which is positioned far upstream from VTN(381–397 a.a.) on
the N-terminal end of VTN. However, Maile and colleagues
also previously described a second integrin-binding site
located within the HBD between amino acids 365 and
38132,33. Indeed, they demonstrated that VTN(365–381 a.a.)
could interact with αVβ3 and that its binding was sufficient
to enhance β3 phosphorylation
32. Considering that the
fragment VTN(381–397 a.a.) belongs to the HBD, we hypo-
thesized that it could interact with integrins through a
different site from the RGD sequence. Therefore, through a
binding competition assay, we explored the interaction
affinity of VTN(381–397 a.a.) with five different integrins: αVβ6,
αVβ3, αVβ5, αVβ1, and α5β1. Whole VTN showed an affinity
for αVβ5 and αVβ6 had a higher affinity for integrin αVβ3, as
previously described9,19,45–48. However, VTN(365–381 a.a.) and
VTN(381–397 a.a.) only showed a high affinity for integrin
αVβ6 in our competition binding model.
Integrin αVβ6 is known to be a key activator of TGF-β1
and plays a significant role in driving fibrosis (e.g., in liver,
lung, and cancer)9,49–51. Indeed, the αVβ6 integrin was
markedly increased in pathological fibrosis and was sug-
gested as a potential therapeutic target. TGF-β1 typically
drives fibrotic processes34 but cannot be considered an
antifibrotic target due to its ubiquitous role in tissue
homeostasis. Fibrosis on synovial tissue was recently
detected in OA and is considered one of the main causes
of joint stiffness and pain6.
Thus, we have made progress by investigating the pre-
sence and regulation of this integrin in human FLSs from
OA patients, which had never been observed before.
Integrin αVβ6 is a heterodimer of noncovalently associated
αV and β6 subunits. Using in vitro and in situ experiments,
we observed the presence of the αVβ6 integrin in
osteoarthritic FLSs and synovial membranes. Although
the presence of other integrins was previously described
in FLSs52, this report is the first to show the presence of
αVβ6 in OA-related synovitis. By IHC, we also observed
the expression of integrin β6 in biopsies of synovial
membranes from the patients with OA, CPPA, and RA.
β6 was positively correlated with the profibrotic marker
α-SMA7 and, to a lesser extent, with the histological
inflammatory score.
In addition, many different mediators of fibrosis,
inflammation, and oxidative stress were tested in vitro to
study the regulation of αVβ6 expression. TGF-β1 was the
only mediator able to increase β6 expression. Notably, the
human FLSs used for this study were derived from OA
patients, and the increase would have probably been more
Fig. 5 Expression of α-SMA in FLSs. Representative images and
quantification of the α-SMA signal after treatment with VTN(381–397)
(10 ng/mL) with or without TGF-β1. Values were normalized to that of
heat shock protein 90 (Hsp90). The results are expressed as the ratio of
the normalized optical density vs. the control and are shown as the
mean (±SEM). *p-value < 0.05; **p-value ≤ 0.01, vs. the control.
Fig. 6 Nano-LC/Chip MS–MS. Quantification of VTN(381–397 a.a.) by
nano-LC/Chip MS–MS. Sera from patients with different chronic
inflammatory diseases were analyzed. The median is indicated.
*p-value ≤ 0.05; **p-value ≤ 0.01; ***p-value ≤ 0.001
(Kolmogorov–Smirnov test). Healthy control (HC), osteoarthritis (OA),
rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus
erythematosus (SLE), systemic sclerosis (SSc).
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striking if we had assessed FLSs from healthy controls.
Anyway, treatment with TGF-β1, a known regulator of
fibrosis, induced a significant increase in the expression of
the β6 subunit. TGF-β1 is required for the expression of
ITGB6 (β6 integrin gene) in epithelial cells, indicating
mutual positive feedback between the two mole-
cules9,53,54. TGF-β1 is produced as a pro-protein that
dimerizes and links to LTBP. This inactive complex made
of TGF-β1, LAP, and LTBP is referred to as a large latent
complex35. Some authors found that organs have much
more TGF-β1 precursor than could be required to trigger
tissue fibrosis. This indicates that the function of this
growth factor in fibrosis is mainly controlled by regulation
of its bioactivation rather than its secretion or synthesis55.
Therefore, we used the TMLC assay to detect the pre-
sence of bioactive TGF-β1 in cell coculture, and we
observed that the presence of human FLSs could activate
added latent TGF-β. The presence of an αVβ6 blocking
antibody in coculture significantly reduced the bioacti-
vation of TGF-β1, supporting the hypothesis that αVβ6
integrin is present on human osteoarthritic FLSs and that
it can mediate TGF-β1 bioavailability. However, the pre-
sence of an αVβ6 antibody in coculture did not completely
abolish TGF-β1 bioactivation because other mechanisms
are probably involved in the activation of latent TGF-β135.
Indeed, αVβ8 is an integrin that has been increasingly
studied in fibrosis for its role as a regulator of TGF-β1.
Unlike αVβ6 and other integrins, αVβ8 appears to be only
devoted to the activation of TGF-β1 and does not interact
with the cytoskeleton56,57. We detected αVβ8 expression
in FLSs by western blotting (we used an anti-β8 mono-
clonal antibody, Abnova, Taipei, Taiwan; data not shown),
and we also observed a significant reduction in the acti-
vation of latent TGF-β1 when an anti-β8 antibody was
used in coculture of FLSs with TMLCs (monoclonal
antibody, Abnova; Supplementary information SI4).
Hence, the sole inhibition of the interaction of αVβ6 with
TGF-β1 cannot be sufficient to completely stop its
bioactivation.
Moreover, considering that the premise of this study
was the interaction of VTN(381–397 a.a.) with the αVβ6
integrin, we examined the effect of this fragment in vitro.
Interestingly, when VTN(381–397 a.a.) was added to cocul-
tures, the luciferase signal significantly decreased, sug-
gesting that this fragment could hamper the interaction of
latent TGF-β1 with αVβ6 integrin on human FLSs in OA.
In this way, we also confirmed in vitro the VTN(381–397 a.a.)
affinity for αVβ6 integrin as previously observed with the
competition study.
Overall, this evidence could indicate a protective role of
the fragment against fibrosis, considering the observed
reduction in latent TGF-β1 activation. However, as
described above, this reduction could be bypassed by
other mechanisms, such as αVβ8. We recently examined
the mechanisms by which VTN(381–397 a.a.) could be
involved in OA. When FLSs were stimulated by
VTN(381–397 a.a.), the expression of the fibrotic marker α-
SMA increased. Interestingly, this effect was observed at a
concentration close to that found in plasma for patholo-
gical conditions. This result is consistent with previous
findings proposing that VTN could exacerbate lung
fibrosis through the upregulation of TGF-β1 signaling and
the increase in α-SMA transcription18. Furthermore, it
has already been proposed that TGF-β1 may induce
myofibroblast differentiation by promoting differential
interaction of integrins with ECM58 and that, in pul-
monary fibrosis, fibroblasts express increased uPAR,
which augments the binding of integrins to ECM pro-
teins59. Thus, we could speculate that VTN(381–397 a.a.)
strengthens the profibrotic TGF-β1 pathway through
αVβ6. Future studies are clearly needed to more deeply
define this role and interaction.
Finally, we aimed to substantiate previous findings15 by
quantifying the presence of VTN(381–397 a.a.) in serum
from patients with OA and other inflammatory chronic
diseases: RA, AS, SLE, and SSc. We applied a method of
nanoliquid chromatography on chip tandem mass spec-
trometry that we formerly developed for the quantifica-
tion of this specific fragment of VTN31. The increased
expression of this peptide with respect to healthy subjects
has been further confirmed in a new cohort of late OA
patients but also in patients with SSc and SLE, while no
rise was observed in patients with RA and AS. Hence,
VTN(381–397 a.a.) cannot be defined as a specific marker of
OA, since it is present in other rheumatic diseases, but its
presence can be related to the typical ECM alteration
present in fibrosis.
In conclusion, these results corroborate our previous
finding that VTN(381–397 a.a.) expression levels are
increased in the serum of OA patients but also in other
rheumatic diseases, such as SSc and SLE. This fragment
can interact with the αVβ6 integrin, a receptor whose
presence was confirmed on FLSs from OA patients and is
involved in the activation of latent TGF-β1, possibly
promoting fibrosis in OA. Taken together, these data
warrant additional studies to unveil the fine molecular
mechanisms that regulate the roles of VTN(381–397 a.a.) and
integrin αVβ6. These findings will contribute to shedding
light on the complexity of fibrosis in OA.
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